Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04999449 · ClinicalTrials.gov registry record · Phase 1
Nebulizer Delivery of Intranasal Scopolamine
A Phase 1 study of Motion Sickness and Scopolamine, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04999449 is a Phase 1 study of Motion Sickness and Scopolamine that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 14 participants, below the 153-participant average among 6 other Motion Sickness trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04999449, a Phase 1 study of Motion Sickness and Scopolamine, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Scopolamine
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04999449
The ClinicalTrials.gov registry entry for NCT04999449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 6 other Motion Sickness trials with a reported enrollment target (91% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Motion Sickness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04999449 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT04999449 about?
NCT04999449 is a clinical study titled "Nebulizer Delivery of Intranasal Scopolamine". To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.
What is the current status of trial NCT04999449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-01-24. Estimated completion is 2025-05-07.
What conditions does trial NCT04999449 study?
This clinical trial studies the following conditions: Motion Sickness, Scopolamine.
What interventions are being tested in trial NCT04999449?
The interventions under investigation include: Placebo (DRUG), Scopolamine (DRUG).
Who is sponsoring clinical trial NCT04999449?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04999449 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
RECRUITING · Phase 2
-
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
RECRUITING · NA
-
Three-Axis Wearable Adaptive Vestibular Stimulator
ACTIVE NOT RECRUITING · NA
-
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
ACTIVE NOT RECRUITING · Phase 3
-
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.